The Food and Drug Administration approved the first-ever drug treatment for Alexander disease on Sept. 3, a rare, progressive and typically fatal genetic neurological disorder that primarily affects children.
Prior to this approval, no treatment options existed for patients diagnosed with the condition, which causes the destruction of white matter in the brain and progressive neurological deterioration. The disease is caused by mutations in the GFAP gene and affects an estimated few thousand patients worldwide.
The approval represents a milestone for the rare disease community, where small patient populations often struggle to attract pharmaceutical research investment. Families affected by Alexander disease have had no therapeutic recourse since the condition was first described in 1949.
The FDA used its authority to expedite review of treatments for serious conditions that fill an unmet medical need. The agency did not specify in its initial announcement whether the approval was granted under accelerated approval, priority review or another expedited pathway.
For the small community of families living with Alexander disease, the approval offers the first pharmacological intervention capable of altering the course of a condition that has been uniformly devastating. Pediatric neurologists have long sought treatment options for the disorder, which can present in infancy, childhood or adulthood with varying degrees of severity.
The approval adds to the FDA’s activity in rare neurological conditions and reflects continued agency focus on diseases affecting pediatric populations. Rare disease drug approvals have increased in recent years as advances in gene therapy and targeted molecular approaches have opened new therapeutic possibilities.
Patient advocacy organizations for Alexander disease are expected to work with the drug’s manufacturer to address access and insurance coverage questions.